Loading…
Back To Schedule
Wednesday, November 20 • 10:20am - 10:40am
Enabling Drug Discovery:Target Validation to PreClinical- Trends in Screening and Compound Profiling

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Improving clinical success rates is a key objective in the pharmaceutical industry, and discovery science platforms continue to deploy new strategies aimed at improving success and translation to the clinic. As with others, we recognized that applying the more relevant cellular translational assays at the earliest points in discovery could allow better decisions earlier in the discovery process, and enable the identification of molecules with improved clinical translation In practice, this opportunity would not only be limited to primary cell or mixed cell culture based translational assays, but could also include broader use of organoids, spheroids, iPSC’s and edited cell lines. However, the costs, the complexity of biology, and especially the limited scalability of cells, limit how these can be used at a scale compatible with high-throughput plate-based HTS formats. We embarked on an ambitious campaign to evaluate ultra low volume platforms that would enable broader use of quantity-limited cell. These technologies have been a focus in the screening field for the past decade, so our work was aligned to evaluate these platforms for use in discovery. A key finding of our evaluation was that the biology is remarkably robust, and the fidelity of the biology was retained in most of the ultraminiaturized experiments. However, while many of the technologies show promise, these are not yet robust production platforms, and technologies for delivering compounds still needs to be addressed.

Speakers
avatar for Jeff Gross

Jeff Gross

Director of Screening, Profiling and Mechanistic Biology, GSK
Jeffrey Gross is a senior director with GlaxoSmithKline, and heads the Screening, Profiling, and Mechanistic Biology group in Upper Providence, PA.  He joined GSK in 2001 after a postdoctoral at the University of Wisconsin.  During his 18 years with GSK, he has worked in early discovery... Read More →

Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 10:20am - 10:40am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA

Attendees (1)